Skip to content

levetiracetam used as first line anti epileptic versus phenobarbitone in neonatal convulsions

A Randomized controlled trial of IV levetiracetam Versus IV phenobarbitone in management of Neonatal Seizures

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013161
Enrollment
100
Registered
2018-04-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Admitted in the NICU with convulsions, not with any life threatening illness/malformation as mentioned in exclusion criteria Health Condition 2: P00-P96- Certain conditions originating in the perinatal period

Interventions

Intervention1: Levetiracetam Phenobarbitone: Intravenous Levetiracetam (LEV) 20mg/kg over 20 min was given to neonates who satisfy the inclusion criteria as first line anti epileptic drug. If there is

Sponsors

Indira Gandhi Institute Of Child Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Neonates with convulsions at admission and not loaded with any anticonvulsant outside

Exclusion criteria

Exclusion criteria: Neonates with: 1) hypoglycemia 2) hypocalcaemia 3) hypomagnesemia Neonates who have received anticonvulsants outside prior to admission Neonates with life threatening conditions and severe congenital malformations

Design outcomes

Primary

MeasureTime frame
1) Whether the presenting convulsion/episode of convulsions was terminated with the drug(s) used. (2) Whether convulsions recurred within 24 hours from termination of the presenting convulsion. (3) The need to use additional antiepileptic drugs to terminate the presenting convulsion. (4) Adverse drug reactions (ADR). 1) Termination of seizures: defined as cessation of seizures 10/20min following administration of drugs LEV/PBTimepoint: 0 hours- At the time of convulsion till time of cessation At 24 hours to look for recurrence

Secondary

MeasureTime frame
Absence of seizures in next 48 hours of administration of drugs Adverse drug reactions observed for each drug during the studyTimepoint: At 48 hours from enrollment to look for any adverse drug reactions and cessation of convulsions

Countries

India

Contacts

Public ContactAyesha Romana

Indira Gandhi Institute of Child Health

drknvraju@yahoo.co.in8884735802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026